Compare REAL & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | AVIR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 434.5M |
| IPO Year | 2019 | 2020 |
| Metric | REAL | AVIR |
|---|---|---|
| Price | $9.85 | $4.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $17.00 | $10.00 |
| AVG Volume (30 Days) | ★ 2.8M | 321.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $692,845,000.00 | $351,367,000.00 |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $10.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $4.71 | $2.78 |
| 52 Week High | $17.39 | $6.45 |
| Indicator | REAL | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 41.41 |
| Support Level | $9.61 | $4.10 |
| Resistance Level | $9.94 | $4.80 |
| Average True Range (ATR) | 0.51 | 0.21 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 82.04 | 34.43 |
The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.